Table 3.
Vascular Parameters at Baseline and Follow-up
| Valsartan (n = 39) | Sacubitril/Valsartan (n = 39) | P Value | |
|---|---|---|---|
| Flow-mediated vasodilation | |||
| FMD (%), baseline | 6.39 ± 3.07 | 6.07 ± 3.62 | 0.67 |
| FMD (%), follow-up | 6.67 ± 2.75 | 6.60 ± 3.89 | 0.94 |
| GTN (%), baseline | 18.94 ± 7.73 | 17.45 ± 6.83 | 0.42 |
| GTN (%), follow-up | 17.57 ± 6.86 | 17.69 ± 6.64 | 0.95 |
| Retinal vessel analysis | |||
| FIDa (%), baseline | 1.36 ± 1.83 | 1.32 ± 1.99 | 0.93 |
| FIDa (%), follow-up | 1.21 ± 1.88 | 1.12 ± 1.90 | 0.84 |
| FIDv (%), baseline | 3.32 ± 2.02 | 3.18 ± 1.34 | 0.72 |
| FIDv (%), follow-up | 3.08 ± 2.10 | 2.41 ± 1.28 | 0.11 |
| Retinal AVR, baseline | 0.86 ± 0.07 | 0.88 ± 0.06 | 0.39 |
| Retinal AVR, follow-up | 0.87 ± 0.09 | 0.88 ± 0.07 | 0.59 |
| Arterial stiffness | |||
| PWV (m/s), baseline | 8.20 ± 2.31 | 7.75 ± 2.47 | 0.45 |
| PWV (m/s), follow-up | 7.92 ± 2.88 | 7.49 ± 2.20 | 0.50 |
| AIXHR75 (%), baseline | 21.83 ± 8.82 | 21.51 ± 11.19 | 0.89 |
| AIXHR75 (%), follow-up | 20.75 ± 9.47 | 18.08 ± 12.44 | 0.31 |
| Blood pressure | |||
| Systolic BP (mm Hg), follow-up | 117 ± 16 | 110 ± 15 | 0.05 |
| Diastolic BP (mm Hg), follow-up | 71 ± 11 | 65 ± 7 | 0.01 |
Values are mean ± SD. Significant differences (P<0.05) are shown in bold.
AIXHR75 = augmentation index normalized to heart rate of 75/min; AVR = arteriovenous ratio; BP = blood pressure; FIDa = flicker-induced dilatation of retinal arterioles; FIDv = flicker-induced dilatation of retinal venules; GTN = glycerol trinitrate-mediated vasodilation; PWV = mean pulse wave velocity.